These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 20402760)

  • 1. Guidelines for treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO; Apostolski S; Evoli A; Gilhus NE; Illa I; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW;
    Eur J Neurol; 2010 Jul; 17(7):893-902. PubMed ID: 20402760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO; Apostolski S; Evoli A; Gilhus NE; Hart IK; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW
    Eur J Neurol; 2006 Jul; 13(7):691-9. PubMed ID: 16834699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune mediated neuromuscular junction defects.
    Farrugia ME; Vincent A
    Curr Opin Neurol; 2010 Oct; 23(5):489-95. PubMed ID: 20651592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.
    van Sonderen A; Wirtz PW; Verschuuren JJ; Titulaer MJ
    Curr Treat Options Neurol; 2013 Apr; 15(2):224-39. PubMed ID: 23263888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the evaluation and therapy of autoimmune neuromuscular junction disorders.
    Katz J; Barohn RJ
    Phys Med Rehabil Clin N Am; 2001 May; 12(2):381-97. PubMed ID: 11345014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune disorders of the neuromuscular junction.
    Lang B; Vincent A
    Curr Opin Pharmacol; 2009 Jun; 9(3):336-40. PubMed ID: 19428298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical aspects of neuromuscular transmission disorders.
    Evoli A
    Acta Neurol Scand Suppl; 2006; 183():8-11. PubMed ID: 16637919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.
    Verschuuren JJ; Palace J; Murai H; Tannemaat MR; Kaminski HJ; Bril V
    Lancet Neurol; 2022 Feb; 21(2):189-202. PubMed ID: 35065041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis and myasthenic syndrome.
    Antozzi C
    Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A; Turbeville S; Lounsbury D
    Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies to ion channels at the neuromuscular junction.
    Lang B; Vincent A
    Autoimmun Rev; 2003 Mar; 2(2):94-100. PubMed ID: 12848965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Bodkin C; Pascuzzi RM
    Neurol Clin; 2021 Feb; 39(1):133-146. PubMed ID: 33223079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The pathophysiology and treatment of autoimmune neuromuscular junction diseases].
    Motomura M
    Rinsho Shinkeigaku; 2011 Nov; 51(11):872-6. PubMed ID: 22277398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system.
    Antozzi C
    Atheroscler Suppl; 2013 Jan; 14(1):219-22. PubMed ID: 23357168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Sanders DB; Guptill JT
    Continuum (Minneap Minn); 2014 Oct; 20(5 Peripheral Nervous System Disorders):1413-25. PubMed ID: 25299290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.